‘First in Human’ Continuous Manufacturing in Biopharmaceuticals — A Conversation with Magnus Schroeder of Just – Evotec Biologics

The bluEPrint by Executive Platforms

At the 2024 edition of the Biomanufacturing World Summit series we sat down with Magnus Schroeder, the VP, Process & Product Design for Just – Evotec Biologics, to talk about some of the advantages of continuous manufacturing in biopharmaceutical manufacturing, especially for companies whose products are approaching the First in Human (FIH) stage. It is never too early to think about process optimization, scalability, and controlling costs, but there is an understandable position where companies focused on the medicine and the science believe that can be sorted out later. Just – Evotec Biologics is a passionate advocate for taking lessons from other industries that build their businesses’ success into the R&D stage of their products’ development. So what does that look like in the Life Sciences? What role do CDMOs need to play to help the industry succeed at this, especially at the crucial FIH stage? For all this and more, give this episode a listen!
--
Magnus Schroeder
VP, Process & Product Design
Just – Evotec Biologics
--
Just – Evotec Biologics, wholly owned by Evotec SE, is a CDMO offering development and manufacturing services for antibody, next-generation biologics, and biosimilar products. We collaborate with partners starting from antibody discovery through process development and manufacturing with sites in US and Europe. We designed our technologies to reduce cost of goods and help expand global access to affordable high-quality biotherapeutics. Our team combines deep industry experience in the fields of data, protein, process, and manufacturing sciences including automation with highly integrated and flexible capabilities to break through the scientific and economic barriers associated with the development of protein therapeutics.